DR. MARC KENNETH WALLACK, M.D.
Radiology at 1 Ave, New York, NY

2006003, Feb 16, 2006

Jul 26, 2005

11/188849

Marc Wallack - New York NY, US
Muthukumaran Sivanandham - S. Ozone Park NY, US

A61K 48/00

424093210, 514044000

An immunotherapeutic vaccine providing antigen presenting cells that have been pulsed with a disrupted cell preparation which includes enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment, the vaccine includes autologous dendritic/monocytic cells (DC/M) that present a mixture of antigens (present in the enucleated cytosol and cell membranes) from melanoma cell lines that have been infected with a recombinant vaccinia virus encoding IL-2. In another of the preferred embodiments, the enucleated cytosol and cell membranes are from melanoma cells harvested from the patient to be treated. A method of making the vaccine and methods of using the vaccine to stimulate an anti-cancer immune response and to treat a patient with a cancer are also described.

7015205, Mar 21, 2006

Oct 18, 2000

09/691504

Marc K. Wallack - New York NY, US
Muthukumaran Sivanandham - S. Ozone Park NY, US

St. Vincent's Hospital and Medical Center of New York - New York NY

A61K 48/00, C12N 5/00, C12N 15/63, C12N 15/87

514 44, 424 932, 424 931, 4353201, 435325, 435455

An immunotherapeutic vaccine providing antigen presenting cells that have been pulsed with a disrupted cell preparation which includes enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment, the vaccine includes autologous dendritic/monocytic cells (DC/M) that present a mixture of antigens (present in the enucleated cytosol and cell membranes) from melanoma cell lines that have been infected with a recombinant vaccinia virus encoding IL-2. In another of the preferred embodiments, the enucleated cytosol and cell membranes are from melanoma cells harvested from the patient to be treated. A method of making the vaccine and methods of using the vaccine to stimulate an anti-cancer immune response and to treat a patient with a cancer are also described.